{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.500","upperLimit":"6.000","value":"1.0000"}]}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.500","upperLimit":"6.020","value":"1.0300"}]}],"title":"Cycle 1, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1 and 15 during each 28-day treatment cycle for all the participants from dose escalation and expansion cohorts were evaluated in this arm group. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.","id":"OG000","title":"Ixazomib 4.0 mg"}],"paramType":"MEDIAN","populationDescription":"PD analysis population: all participants who received at least 1 dose of ixazomib and had whole blood 20S proteasome inhibition-time data and dosing data to permit calculation of PD parameters. Data was only collected for ixazomib 4.0 mg arm group. Number analyzed is number of participants with evaluable data at given time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr","title":"TEmax: Time to Maximum Observed Effect (Emax) of Whole Blood 20S Proteasome Inhibition for Ixazomib","type":"SECONDARY","unitOfMeasure":"hours"}